Vaibhav Sahai, MD
Medical Oncology · Ann Arbor, MINPI 1992904023
Payments from drug & device makers
Across 231 payments — averaging $23,214 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$4.4M
- Servier Bioinnovation$186K
- Clovis Oncology, Inc.$140K
- Incyte Corporation$126K
- Servier Pharmaceuticals LLC$99K
- Exelixis Inc.$87K
- plus $351K from 18 others
Across 1 payment — averaging $2866.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3K
What the payments were for
- Consulting fees$58,38373%
- Speaking & faculty fees$13,13417%
- Travel & lodging$6,8909%
- Food & beverage$1,1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 50 | $4,372,683 |
| Servier Bioinnovation | 10 | $186,249 |
| Clovis Oncology, Inc. | 2 | $140,159 |
| Incyte Corporation | 80 | $126,476 |
| Servier Pharmaceuticals LLC | 4 | $98,643 |
| Exelixis Inc. | 10 | $87,165 |
| Boehringer Ingelheim | 3 | $67,507 |
| Agios Pharmaceuticals, Inc. | 26 | $57,101 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54,396 |
| Servier Affaires Medicales | 4 | $33,327 |
| Jazz Pharmaceuticals Inc. | 7 | $32,921 |
| Bristol Myers Squibb | 4 | $25,078 |
| Biontech SE | 1 | $22,310 |
| Halozyme Inc | 5 | $21,592 |
| AstraZeneca | 7 | $12,870 |
| Novartis | 1 | $7,359 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $3,150 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $2,929 |
| GSK | 1 | $2,600 |
| Delcath Systems | 1 | $2,500 |
| Astrazeneca UK Limited | 1 | $2,398 |
| Taiho Oncology, Inc. | 2 | $1,742 |
| Boehringer Ingelheim International GmbH | 1 | $597 |
| Astrazeneca AB | 3 | $590 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,362,340 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 44 | $101,633 |
| ZenpepLipase/Protease/Amylase | 20 | $86,520 |
| EliquisApixaban | 41 | $25,662 |
| Prochlorperazine Maleate | 28 | $608 |
| Ondansetron Hcl | 29 | $341 |
| Olanzapine | 15 | $305 |
| Omeprazole | 24 | $288 |
| Gabapentin | 16 | $193 |
| Levothyroxine Sodium | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ann Arbor
- Moshe TalpazAnn Arbor$13.7M
- Zachery ReichertAnn Arbor$10.6M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Francis WordenAnn Arbor$4.2M
- Harry ErbaAnn Arbor$4.1M
- Angel QinAnn Arbor$3.3M
- Maha HussainAnn Arbor$3M
- Gregory KalemkerianAnn Arbor$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.